| Affiliation: | (1) Section of Neurosurgery, Department of Clinical Neuroscience, Karolinska Institutet and Hospital, Stockholm, Sweden;(2) Service de Reanimation, Military Teaching Hospital, Toulon-Naval, France;(3) Section of Neurosurgery, Department of Neuroscience, Uppsala University, Uppsala, Sweden;(4) Academic Department of Neurosurgery, Addenbrooke!["rsquo"]("/content/r13tx449hux1170y/xlarge8217.gif") s Hospital, Cambridge, UK;(5) Department of Clinical Neuroscience, Lund University Hospital, Lund, Sweden;(6) Department of Neurosurgery, Baylor College of Medicine, Houston, Tex., USA;(7) Department of Neurosurgery, Vall dHebron University Hospitals, Barcelona, Spain;(8) Department of Neuroanaesthesia, National Hospital for Neurology and Neurosurgery, London, UK;(9) Department of Anaesthesia and Intensive Care, Ospedale Maggiore Policlinico IRCCS, Milan, Italy;(10) Department of Physiology and Pharmacology, Karolinska institutet, Nanna Svartz väg 2, 17177 Stockholm, Sweden;(11) Neurochirurgische Klinik und Poliklinik, Universitatsklinikum Heidelberg, Heidelberg, Germany;(12) Department of Neuroanaesthesia, Copenhagen University Hospital, Copenhagen, Denmark |
| Abstract: | ![]()
Background Microdialysis is used in many European neurointensive care units to monitor brain chemistry in patients suffering subarachnoid hemorrhage (SAH) or traumatic brain injury (TBI).Discussion We present a consensus agreement achieved at a meeting in Stockholm by a group of experienced users of microdialysis in neurointensive care, defining the use of microdialysis, placement of catheters, unreliable values, chemical markers, and clinical use in SAH and in TBI.Conclusions As microdialysis is maturing into a clinically useful technique for early detection of cerebral ischemia and secondary brain damage, there is a need to following such definition regarding when and how to use microdialysis after SAH and TBI. |
